Gialurom injection in / Soest. 1.5% 2ml syringe 1 pc

$155.30

Gialurom injection in / Soest. 1.5% 2ml syringe 1 pc

5 in stock

Quantity:

Description

Composition
Active substance:
1 the syringe comprises sodium hyaluronate 30 mg, 18 mg sodium chloride.
Excipients:
Water for injection, to achieve a sufficient drug volume of 2 ml.
Description:
A solution for intraarticular administration GIALUROM – 1.5% sodium hyaluronate solution in disposable syringes of 2 ml is a sterile viscoelastic solution of sodium hyaluronate. Sodium hyaluronate obtained by bacterial fermentation. Sodium hyaluronate is a polysaccharide GIALUROM identical human, consists of repeating disaccharide units Natsetilglikozamina and sodium glucuronate having a molecular weight greater than 2,400,000 Da. Sodium hyaluronate is present everywhere in the human body and is present in high concentrations in the tissues, such as vitreous humor, synovial fluid, umbilical cord and dermis. The sodium hyaluronate synovial fluid acts as a lubricant and shock absorber, which promotes normal movement without pain. When disease such as arthritis, viscoelasticity of the synovial fluid is reduced, so that significantly increases the mechanical load on the joint and enhanced destruction of articular cartilage, and the restriction is manifested pain at movement in joints. Lubricating and cushioning effect of the drug alleviate pain and improve joint mobility with intra-articular administration. These effects last for more than 6 months after a single treatment.
Product form:
A solution for intraarticular administration GIALUROM available as a pre-filled disposable syringes which contain 2 ml of sterile, viscoelastic solution of sodium hyaluronate. Each milliliter of solution “GIALUROM” contains 15 mg of sodium hyaluronate, 9 mg of sodium chloride and water for injectable solutions. Package Size: 1 or 3 prefilled syringe in a pack made of cardboard.
Contraindications
Individual intolerance (including a history of hypersensitivity) components GIALUROM solution; for infected wounds, abrasions in the joint; infectious diseases of the joints; known systemic bleeding disorders. GIALUROM may contain traces of bacterial proteins and is contraindicated in patients with known hypersensitivity appropriate.
Dosage
15 mg / ml
Indications
GIALUROM solution was used as the viscoelastic agent for substitution of the synovial fluid for pain caused by degenerative diseases synovial joints, such as osteoarthritis or osteoarthrosis. By its action GIALUROM drug serves as a lubricant and a mechanical support for the patient’s joint.
GIALUROM solution was introduced into human joints: the pain and restricted mobility due to degenerative-dystrophic changes and traumatic knee, hip and other joints synovial; temporary replacement or supplement of synovial fluid; in the treatment of patients with active lifestyle and regularly of loading the affected joint.
side effects
Sodium hyaluronate is characterized by excellent tolerability. Occurrence of local secondary effects such as pain, feeling of warmth, redness and swelling may occur at the joint, into which the drug (superposition joint ice for five – ten minutes to remove all such phenomena). allergic reactions may occur very rarely. With intraarticular injection there are minimal risks of infection and bleeding.
special instructions
GIALUROM solution is only intended for single use. Do not reuse. The use of open and / or damaged sterile packaging is not allowed. Re-sterilization is not allowed. The drug is administered only if the solution is clear.
PRECAUTIONARY MEASURES:
You need to follow the introduction of the scheme and the rules of aseptic and antiseptic with intraarticular injection. Injection of sodium hyaluronate should be performed exclusively by physicians and certified certificated corresponding profile. Do not use sodium hyaluronate in an excessive amount, carefully monitor patients. Do not overload interarticular space. If the pain increases during insertion, the procedure should be stopped. Before applying the solution GIALUROM patients should be evaluated for signs of acute inflammation, and the physician must determine the possibility and the treatment regimen of patients given the drug. As after any other invasive procedures at the joint, after injection of sodium hyaluronate, the patient is advised to adhere gentle treatment and to avoid excessive load on the joint within a few days. Patients with painful consequences after intraarticular injection of sodium hyaluronate should immediately consult a doctor. Until today, there are not sufficient data to recommend the use of this drug in children and adolescents. Do not use GIALUROM simultaneously or in admixture with other drugs intended for intra-articular application.
Storage conditions
Store at a temperature below 25 C, in the original package, in a dry place. Do not freeze. Keep out of the reach of children. Do not use after the expiration date.
Dosing and Administration
GIALUROM injections made by specialist doctors. GIALUROM solution is only intended for intra-articular application. Do not use intravenously.
Introduction of sodium hyaluronate is carried out at room temperature. Injected volume depends on the size of the joint, but does not exceed 2 ml into the knee joint and other large joints, or 1 ml for small joints. The doctor is responsible for the establishment of the applicable amount and have to make sure that the joint is not overloaded.
GIALUROM solution is introduced into the cavity of the joint once a week for 3 consecutive weeks. The simultaneous treatment of multiple joints. it is impossible to carry out a repeated cycle of treatment earlier than 6 months for the same joint. Before using the product GIALUROM, fluid accumulation in the joint should be removed by sucking syringe. GIALUROM solution discharged in a pre-filled syringe, which is not necessary to dilute the contents. The drug is sterile and should be used immediately after opening the package. The drug is intended for single use only. GIALUROM should be carefully introduced into the joint cavity, carefully following the introduction scheme. The introduction is an aseptic procedure, therefore, observe proper precautions. Ready sterile syringe is removed from its case, the cap is removed and then put on a sterile needle, which is fixed by a slight twist. Before the introduction is necessary to remove air from the syringe.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Rompharm

There are no reviews yet.

Add your review